EverSource Wealth Advisors LLC decreased its position in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) by 37.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 18,092 shares of the exchange traded fund’s stock after selling 10,626 shares during the quarter. EverSource Wealth Advisors LLC’s holdings in SPDR S&P Biotech ETF were worth $2,311,000 as of its most recent SEC filing.
Several other large investors have also recently made changes to their positions in XBI. Empire Financial Management Company LLC grew its position in SPDR S&P Biotech ETF by 4.1% during the first quarter. Empire Financial Management Company LLC now owns 19,125 shares of the exchange traded fund’s stock valued at $2,443,000 after buying an additional 750 shares during the period. Evercore Wealth Management LLC grew its position in shares of SPDR S&P Biotech ETF by 60.2% during the 1st quarter. Evercore Wealth Management LLC now owns 3,992 shares of the exchange traded fund’s stock valued at $510,000 after acquiring an additional 1,500 shares during the period. KCM Investment Advisors LLC grew its position in shares of SPDR S&P Biotech ETF by 88.5% during the 1st quarter. KCM Investment Advisors LLC now owns 3,533 shares of the exchange traded fund’s stock valued at $451,000 after acquiring an additional 1,659 shares during the period. Quantinno Capital Management LP increased its stake in shares of SPDR S&P Biotech ETF by 54.5% in the 1st quarter. Quantinno Capital Management LP now owns 2,996 shares of the exchange traded fund’s stock valued at $383,000 after purchasing an additional 1,057 shares in the last quarter. Finally, Gateway Wealth Partners LLC purchased a new position in shares of SPDR S&P Biotech ETF in the 1st quarter valued at about $1,525,000.
SPDR S&P Biotech ETF Trading Down 1.2%
Shares of XBI stock opened at $147.91 on Thursday. The company has a market capitalization of $9.73 billion, a P/E ratio of 11.47 and a beta of 0.82. The business’s 50 day moving average is $145.48 and its two-hundred day moving average is $134.07. SPDR S&P Biotech ETF has a 12-month low of $84.39 and a 12-month high of $165.71.
SPDR S&P Biotech ETF Company Profile
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.
See Also
- Five stocks we like better than SPDR S&P Biotech ETF
- Why SK hynix Could Be the Best AI Chip Stock to Buy Now
- Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters
- Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead?
- Why Bloom Energy May Be the Most Important AI Infrastructure Stock
Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report).
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.
